Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway

Clinical studies have shown that dapagliflozin can reduce cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM), but the exact mechanism is unclear. In this study, we used the molecular docking and network pharmacology methods to explore the potential mechanism of dapagliflozin on...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Zhaodi, Li, Li, Fu, Hui, Yin, Yanyan, Du, Bingyu, Wang, Fangqi, Ding, Yi, Liu, Yibo, Zhao, Renjie, Zhang, Zhongwen, Yu, Shaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335696/
https://www.ncbi.nlm.nih.gov/pubmed/34258872
http://dx.doi.org/10.1111/jcmm.16786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335696/
https://www.ncbi.nlm.nih.gov/pubmed/34258872
http://dx.doi.org/10.1111/jcmm.16786

Ejemplares similares